TITLE

Noteworthy

PUB. DATE
May 2008
SOURCE
Pharmaceutical Representative;May2008, Vol. 38 Issue 5, p15
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers news briefs in the U.S. related to pharmacology. It is published in "The Journal of the American Medical Association's" letter to the editor, that placebo is still prevailing for patients who cannot afford to buy expensive medicine. According to "Pediatrics" journal, that eating breakfast everyday could reduce the risk of obesity in teenagers. It is reported that there are less than one third population of the U.S. citizens are aware of the five deadly signs of heart attack.
ACCESSION #
31900667

 

Related Articles

  • One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. Hansteen, V.; Moinichen, E.; Lorentsen, E.; Strom, O.; Soiland, K.; Dyrbekk, D.; Refsum, A.-M.; Tromsdal, A.; Knudsen, K.; Eika, C.; Jun, J. Bakken; Smith, P.; Hoff, P.I. // British Medical Journal (Clinical Research Edition);1/16/1982, Vol. 284 Issue 6310, p155 

    Investigates the effects of propranolol and placebo on patients with history of myocardial infarction in Norway. Rate of mortality; Reduction in sudden cardiac deaths among high risk patients treated with propanol; Benefits of long-term beta-adrenoceptor blockade in low-risk patients.

  • Long term propranolol treatment and changes in body weight after myocardial infarction. Rossner, Stephen; Taylor, Carol L.; Byington, Robert P.; Furberg, Curt D. // BMJ: British Medical Journal (International Edition);4/7/90, Vol. 300 Issue 6729, p902 

    Examines the effect of long term propranol treatment and changes in the body weight after myocardial infarction. Analysis of placebo controlled data; Changes in the body weight; Implication in diuretics or physical activity.

  • Second opinion.  // Mayo Clinic Health Letter;Sep2000, Vol. 18 Issue 9, p8 

    Answers questions related to the risk factor of heart attack and the concept of placebo. Reasons for taking extra iron in the body; Advantage of iron intake for people with hemochromatosis; Correlation between heme iron and heart attack risk; Definition of placebo; Administration of placebo or...

  • Clinical Trials Update. Slomski, Anita // JAMA: Journal of the American Medical Association;3/24/2015, Vol. 313 Issue 12, p1200 

    This section offers U.S. medical news briefs. A report published in a 2015 issue of "JAMA Psychiatry" revealed that a clinical trial found that lisdexamfetamine dimesylate was effective in decreasing binge-eating days relative to placebo in patients with binge-eating disorder. A report published...

  • Noteworthy.  // Pharmaceutical Representative;Mar2008, Vol. 38 Issue 3, p13 

    The article offers information on various medical research. It presents a study of elderly male participants, which assesses the relationship between individuals' scores on four measures of anxiety and incidence of myocardial infarction. It also cites a survey which identifies the therapeutic...

  • Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. Mega, Jessica L.; Braunwald, Eugene; Wiviott, Stephen D.; Bassand, Jean-Pierre; Bhatt, Deepak L.; Bode, Christoph; Burton, Paul; Cohen, Marc; Cook-Bruns, Nancy; Fox, Keith A.A.; Goto, Shinya; Murphy, Sabina A.; Plotnikov, Alexei N.; Schneider, David; Sun, Xiang; Verheugt, Freek W.A.; Gibson, C. Michael // New England Journal of Medicine;1/5/2012, Vol. 366 Issue 1, p9 

    Background: Acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in patients with a recent acute coronary...

  • Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. Clemens, Andreas; Fraessdorf, Mandy; Friedman, Jeffrey // Vascular Health & Risk Management;2013, Vol. 9, p599 

    Background: Dabigatran 150 mg twice daily was shown to be superior to warfarin in preventing stroke in subjects with nonvalvular atrial fibrillation (SPAF) in the RE-LY (Randomized Evaluation of Long-term anticoagulation therapY) trial. Numerically, more myocardial infarctions occurred in...

  • Atorvastatin Reload Prior to PCI for Patients on Chronic Statin Therapy. Boyle, Andrew J. // Clinical Cardiology Alert;Oct2009, Vol. 28 Issue 10, p73 

    The article discusses the study "Efficacy of Atorvastatin Reload in Patients on Chronic Statin Therapy Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial." The study aimed to...

  • The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393].  // BMC Medicine;2005, Vol. 3, p6 

    Background: There have been concerns that low blood cholesterol concentrations may cause nonvascular mortality and morbidity. Randomisation of large numbers of people to receive a large, and prolonged, reduction in cholesterol concentrations provides an opportunity to address such concerns...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics